This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Catalog
ASAP is committed to accelerating the pace of discovery and informing a path to a cure for Parkinson’s disease through collaboration, research-enabling resources, and data sharing. We’ve created this catalog to showcase the research outputs and tools developed by ASAP-funded programs.
Article
Is Tau the Initial Pathology in Dopaminergic Nigrostriatal Degeneration? Studies in Parkinsonism and Parkinson’s Disease
Preprint: Here, the authors look at whether nigrostriatal dopaminergic neurodegeneration occurs independently of alpha-synuclein aggregation for those living with PD. Their findings suggest that it is independent and likely tau mediated.
Teams
Dataset
Nigrostriatal Tau pathology in Parkinsonism and Parkinson’s disease
Dataset corresponding to the preprint, “Is Tau the Initial Pathology in Dopaminergic Nigrostriatal Degeneration? Studies in Parkinsonism and Parkinson’s Disease.”
Teams
Protocol
Calf intestine alkaline phosphatase (CIAP) treatment
Alpha-synuclein phosphorylated at serine 129 (PSER129) occurs in two pools, non-aggregated (physiological) and aggregated (disease). This protocol allows for the selective dephosphorylation of non-aggregated PSER129 and enhances the specificity and sensitivity immunodetection of aggregated PSER129. Thus, this protocol can be used to differentiate physiological from aggregated PSER129.
Teams
Protocol
Multiplex labeling with tyramide fluorophores (Free-floating tissues) – Killinger Lab 2024
This protocol details the multiplex labeling of free-floating tissues using tyramide fluorophores in the Killinger Lab (2024).
Teams
Article
Neither alpha-synuclein fibril strain nor host murine genotype influences seeding efficacy
For unclear reasons, PD patients with certain GBA1 mutations (GBA-PD) have a more aggressive clinical progression. The authors tested the two hypotheses for why this occurs; that GBA1 mutations promote αsyn spread or drive the generation of highly pathogenic αsyn polymorphs (i.e., strains).
Teams
Protocol
Rotarod
Rotarod protocol optimized for mice. This test is made to assess motor coordination and balance. The results should show lower latency-to-fall numbers for mice with motor impairments.
Teams
Protocol
Purification of proteins from PFA-fixed samples
This protocol details the purification of proteins from PFA-fixed samples and the extraction of proteins from formalin-fixed tissues. Also includes the biotin pulldown prior to LC-MS/MS. Samples generated for this protocol have been used for mass spectrometry, immunoblotting, and pulldowns.
Teams
Article
Nigrostriatal tau pathology in parkinsonism and Parkinson’s disease
Here, the authors demonstrate that loss of nigral dopaminergic neurons, loss of putamenal dopaminergic innervation, and loss of the tyrosine hydroxylase-phenotype in the substantia nigra and putamen occur equally in mild motor deficit groups with and without nigral alpha-synuclein aggregates.
Teams
Article
Alpha-synuclein aggregates are phosphatase resistant
Phosphorylation of αsyn at serine 129 (PSER129) was considered rare in the healthy human brain but is enriched in pathological αsyn aggregates and is used as a marker for disease inclusions. Recent observations challenge this assumption. The authors investigated conditions under which PSER129 could be detected in the mammalian brain.
Teams